Gary A. Ulaner

1 month ago | jnm.snmjournals.org | Gary A. Ulaner |Jason Lewis |Ola Landgren |Molecular Imaging

Currently, the determination of disease burden in multiple myeloma is suboptimal. Myeloma cells may not secrete abnormal immunoglobulins or free light chains, limiting blood and urinary analysis (1). Imaging by radiography and MRI is limited, and approximately 30% of myeloma lesions are not appreciable by 18F-FDG PET (2). Bone marrow biopsies are also limited by the limited sites that can be sampled (3). Thus, better methods of detecting, localizing, and quantitating myeloma cells are needed.